enGene Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
enGene Therapeutics Inc. (ENGN) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price of $6.99 per share as of 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice · last filed 2026-09-08
- 2026-07-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $6.99.
- 2026-04-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $6.77.
- 2026-01-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $6.46.
- 2025-10-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $6.07.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2026-07-31 | $6.99 10-Q · filed 2026-09-08 |
| 2026-04-30 | $6.77 10-Q · filed 2026-06-15 |
| 2026-01-31 | $6.46 10-Q · filed 2026-03-09 |
| 2025-10-31 | $6.07 10-K · filed 2025-12-22 |
| 2025-07-31 | $4.81 10-Q · filed 2025-09-11 |
| 2025-04-30 | $4.10 10-Q · filed 2025-06-12 |
| 2025-01-31 | $3.31 10-Q · filed 2025-03-10 |
| 2024-10-31 | $2.32 10-K · filed 2024-12-19 |
| 2024-07-31 | $2.29 10-Q · filed 2024-09-10 |
| 2024-04-30 | $2.10 10-Q · filed 2024-06-14 |
| 2024-01-31 | $0.66 10-Q · filed 2024-03-11 |
| 2023-10-31 | $1.26 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |